|
|
|
|
LEADER |
04859nam a2201033Ia 4500 |
001 |
10.1002-jcla.23963 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 08878013 (ISSN)
|
245 |
1 |
0 |
|a IL-23/IL-17 axis and soluble receptors isoforms sIL-23R and sIL-17RA in patients with rheumatoid arthritis-presenting periodontitis
|
260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1002/jcla.23963
|
520 |
3 |
|
|a Background: Rheumatoid arthritis (RA) and periodontitis (P) are chronic inflammatory diseases characterized by joint and radiographic bone loss, respectively. IL-23 and IL-17 have an essential role in the immunopathogenesis of RA, and P. IL-23 stimulates Th17 cells through which produces IL-17, IL-21, and RANKL. IL-17 stimulates fibroblasts to produce RANKL, which initiates bone loss in the joints in RA and the periodontal tissue in periodontitis. The aim of this study was to determine the expression pattern of IL-23/IL-17 axis and soluble receptors isoforms sIL-23R and sIL-17RA of patients with RA presenting P (RAP). Material and methods: Healthy subjects (HS) (n = 42), patients with P (n = 40), RA (n = 20), and patients with RAP (n = 40) were included. Plasma samples were obtained to evaluate the IL-23, IL-17A, sIL-23R, and sIL-17RA by ELISA technique. A nonparametric Mann-Whitney U test was used to compare the differences between groups. A Chi-square was used to compare gender, grade and stage of periodontitis, and DAS28-ESR between the groups. Spearman's rank correlation coefficient was used to study the association between the molecules and clinical parameters. Results: IL-23 levels were increased in the RAP group, and lower sIL-23R levels were found in the RAP groups. However, IL-17A was lower in the P and RAP group but not in RA patients. RAP group showed a decrease IL-17A levels in advanced stages of the periodontal disease. Conclusion: These results suggest that IL-23 and IL-17A tend to downregulate their expression patterns when patients present both rheumatoid arthritis and periodontitis. © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a Adult
|
650 |
0 |
4 |
|a Arthritis, Rheumatoid
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a biological marker
|
650 |
0 |
4 |
|a Biomarkers
|
650 |
0 |
4 |
|a blood
|
650 |
0 |
4 |
|a blood sampling
|
650 |
0 |
4 |
|a C reactive protein
|
650 |
0 |
4 |
|a case control study
|
650 |
0 |
4 |
|a Case-Control Studies
|
650 |
0 |
4 |
|a chi square test
|
650 |
0 |
4 |
|a complication
|
650 |
0 |
4 |
|a controlled study
|
650 |
0 |
4 |
|a correlation coefficient
|
650 |
0 |
4 |
|a Cross-Sectional Studies
|
650 |
0 |
4 |
|a cross-sectional study
|
650 |
0 |
4 |
|a DAS28
|
650 |
0 |
4 |
|a disease classification
|
650 |
0 |
4 |
|a enzyme linked immunosorbent assay
|
650 |
0 |
4 |
|a erythrocyte sedimentation rate
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a Female
|
650 |
0 |
4 |
|a Health Assessment Questionnaire
|
650 |
0 |
4 |
|a Health Assessment Questionnaire Disability Index
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a IL-17A
|
650 |
0 |
4 |
|a IL17A protein, human
|
650 |
0 |
4 |
|a IL17RA protein, human
|
650 |
0 |
4 |
|a IL-23
|
650 |
0 |
4 |
|a IL23A protein, human
|
650 |
0 |
4 |
|a IL23R protein, human
|
650 |
0 |
4 |
|a interleukin 17
|
650 |
0 |
4 |
|a interleukin 17
|
650 |
0 |
4 |
|a interleukin 17 receptor
|
650 |
0 |
4 |
|a interleukin 17 receptor
|
650 |
0 |
4 |
|a interleukin 17 receptor A
|
650 |
0 |
4 |
|a interleukin 23
|
650 |
0 |
4 |
|a interleukin 23 receptor
|
650 |
0 |
4 |
|a interleukin 23p19
|
650 |
0 |
4 |
|a interleukin receptor
|
650 |
0 |
4 |
|a Interleukin-17
|
650 |
0 |
4 |
|a Interleukin-23 Subunit p19
|
650 |
0 |
4 |
|a major clinical study
|
650 |
0 |
4 |
|a male
|
650 |
0 |
4 |
|a Male
|
650 |
0 |
4 |
|a pathology
|
650 |
0 |
4 |
|a periodontitis
|
650 |
0 |
4 |
|a periodontitis
|
650 |
0 |
4 |
|a Periodontitis
|
650 |
0 |
4 |
|a prognosis
|
650 |
0 |
4 |
|a Prognosis
|
650 |
0 |
4 |
|a protein blood level
|
650 |
0 |
4 |
|a protein expression
|
650 |
0 |
4 |
|a rank sum test
|
650 |
0 |
4 |
|a Receptors, Interleukin
|
650 |
0 |
4 |
|a Receptors, Interleukin-17
|
650 |
0 |
4 |
|a rheumatoid arthritis
|
650 |
0 |
4 |
|a rheumatoid arthritis
|
650 |
0 |
4 |
|a rheumatoid arthritis-presenting periodontitis
|
650 |
0 |
4 |
|a rheumatoid factor
|
650 |
0 |
4 |
|a sIL-17RA
|
650 |
0 |
4 |
|a sIL-23R
|
650 |
0 |
4 |
|a staging
|
650 |
0 |
4 |
|a swollen joint count
|
650 |
0 |
4 |
|a tender joint count
|
650 |
0 |
4 |
|a unclassified drug
|
650 |
0 |
4 |
|a visual analog scale
|
700 |
1 |
|
|a Bernard-Medina, A.G.
|e author
|
700 |
1 |
|
|a Gómez-Meda, B.C.
|e author
|
700 |
1 |
|
|a Guerrero-Velázquez, C.
|e author
|
700 |
1 |
|
|a Martínez-Rodríguez, V.M.D.C.
|e author
|
700 |
1 |
|
|a Oregon-Romero, E.
|e author
|
700 |
1 |
|
|a Pita-López, M.L.
|e author
|
700 |
1 |
|
|a Rodríguez-Montaño, R.
|e author
|
773 |
|
|
|t Journal of Clinical Laboratory Analysis
|